Screener
Ligand Pharmaceuticals LGND Total Equity
Total Equity at other companies
Other financials
Where this comes from
Reported directly by Ligand Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:StockholdersEquity.
The source filing: Ligand Pharmaceuticals’s 10-Q, filed August 7, 2026. Open the filing →
- Filed
- Aug 7, 2026, 4:06 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0000886163-26-000044
FAQ
- What is Ligand Pharmaceuticals's total equity?
- Ligand Pharmaceuticals (LGND) reported total equity of $967.52M in Q2 2026.
- How has Ligand Pharmaceuticals's total equity changed year-over-year?
- Ligand Pharmaceuticals's total equity increased by 16.9% year-over-year, from $827.31M to $967.52M.
- What is the long-term trend for Ligand Pharmaceuticals's total equity?
- Over 5 years (2020 to 2025), Ligand Pharmaceuticals's total equity has grown at a 7.5% compound annual growth rate (CAGR), from $709.53M to $1.02B.
- What does total equity mean?
- Net assets attributable to shareholders — total assets minus total liabilities. Represents the book value of shareholders' ownership claim.
Ask your AI about Ligand Pharmaceuticals's total equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude